1. Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1)
   Khatera Rahmani et al, 2017, Biochemical and Biophysical Research Communications CrossRef
2. Expression of CRM1 and CDK5 shows high prognostic accuracy for gastric cancer
   Yu-Qin Sun et al, 2017, WJG CrossRef
3. Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53’s tumor suppression
   Józefa Węsierska-Gądek, 2018, Future Medicinal Chemistry CrossRef
4. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
   null Birnbaum et al, 2019, JCM CrossRef
5. Inhibiting cancer cell hallmark features through nuclear export inhibition
   Qingxiang Sun et al, 2016, Sig Transduct Target Ther CrossRef
6. Selective Inhibitors of Nuclear Export in the treatment of hematological malignancies
   Alessandro Allegra et al, 2019, Clinical Lymphoma Myeloma and Leukemia CrossRef
7. BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression
   David Wiener et al, 2015, Breast Cancer Res Treat CrossRef
8. Targeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential
   Tamara Stelma et al, 2016, IUBMB Life CrossRef
9. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
   Vincent Camus et al, 2017, J Hematol Oncol CrossRef
10. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
    Han Bit Baek et al, 2018, Oncotarget CrossRef
11. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
    Jasper Edgar Neggers et al, 2016, Oncotarget CrossRef
12. A Radiosensitivity Gene Signature and XPO1 Predict Clinical Outcomes for Glioma Patients
    Shan Wu et al, 2020, Front. Oncol. CrossRef
13. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia
    Thomas Vercruysse et al, 2017, Clin Cancer Res CrossRef
14. The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
    Justin T Breitbach et al, 2021, Vet Comp Oncol CrossRef
15. The Mammalian Ecdysoneless Protein Interacts with RNA Helicase DDX39A To Regulate Nuclear mRNA Export.
    Irfana Saleem et al, 2021, Mol Cell Biol CrossRef
16. Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies
    Sanmei Wang et al, 2021, Oncol Rep CrossRef
17. Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkers
    Pauline J. Watt et al, 2021, Int. J. Cancer CrossRef
18. Targeting XPO1-Dependent Nuclear Export in Cancer
    Ekaterina Kim et al, 2022, Biochemistry Moscow CrossRef
19. Modulating undruggable targets to overcome cancer therapy resistance
    Catherine Passirani et al, 2022, Drug Resistance Updates CrossRef
20. Prognostic and therapeutic significance of XPO1 in T-cell lymphoma
    Danian Nie et al, 2022, Experimental Cell Research CrossRef
21. A mass spectrometry-based approach for the identification of Kpnβ1 binding partners in cancer cells
    Michael O. Okpara et al, 2022, Sci Rep CrossRef
22. Protein-protein interaction and interference of carcinogenesis by supramolecular modifications
    Oluwatosin A. Saibu et al, 2023, Bioorganic & Medicinal Chemistry CrossRef
23. Clinicopathological and prognostic significance of XPO1 in solid tumors: meta-analysis and TCGA analysis
    Yang Tan et al, 2023, Expert Review of Molecular Diagnostics CrossRef
24. Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells
    Jing Xu et al, 2023, Exp Ther Med CrossRef
25. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
    Stella Newell et al, 2024, IUBMB Life CrossRef
26. The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials
    Chuanxi Lai et al, 2024, Clinical & Translational Med CrossRef
27. Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?
    Celia María Curieses Andrés et al, 2024, IJMS CrossRef
28. Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?
    Viktorija Sokolova et al, 2025, Mol Biol Rep CrossRef